Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 275

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 275
---
 |               |       — |     |              |      — |     |       |       — |

| (1) | Amounts reported in this column represent the aggregate grant date fair value of the stock option awards                                                                                                                                   
 granted to Mr. Garland and Dr. Ruffolo, Jr. during 2024 as determined in accordance with FASB ASC Topic 718. Assumptions used in the calculations of these amounts are included in Note 10 to our audited financial statements included in 
 this registration statement. The amounts do not reflect the actual economic value that may be realized by Mr. Garland or Dr. Ruffolo, Jr.                                                                                                  |

| (2) | Includes consulting fees of $3,500 per month paid to Dr. Ruffolo, Jr. for clinical consulting services provided 
 to us.                                                                                                          |

| (3) | The aggregate number of shares issuable upon exercise of option awards outstanding at December 31, 2024                                                                                                                                    
 for Mr. Garland was 21,514, none of which were vested. 25% of each of the option awards vests upon the first anniversary of the grant date, and the remainder vests and becomes exercisable in thirty-six (36) substantially equal monthly 
 installments thereafter.                                                                                                                                                                                                                   |

| (4) | The aggregate number of shares issuable upon exercise of option awards outstanding at December 31, 2024                                                                                                                                        
 for Dr. Ruffolo, Jr. was 13,266, 2,510 of which were fully vested. 25% of the option awards vests upon the first anniversary of the grant date, and the remainder vests and becomes exercisable in thirty-six (36) substantially equal monthly 
 installments thereafter.                                                                                                                                                                                                                       |

Ms. Turner, our current Chief Executive Officer, and Mr. Prensky, our former Chief Executive Officer, each of whom is also a director, did not receive any additional compensation for their respective service as directors in 2024. Ms. Turner and Mr. Prensky’s compensation as named executive officers in 2024 is set forth below under “Executive Compensation—Summary Compensation Table.” 187

Non-EmployeeDirector Compensation Policy In August 2025, our board of directors approved a non-employee directorcompensation policy that we expect will become effective in connection with this offering. Under the non-employee directorpolicy, our directors who are not also serving as employees of or consultants to us will be eligible to receive the compensation summarized below for service on our